Holen Sie sich die Stockscreener-App
6.63
4.09%
0.28
Schlusskurs vom Vortag:
$6.35
Offen:
$6.29
24-Stunden-Volumen:
9,714
Relative Volume:
0.24
Marktkapitalisierung:
$29.81M
Einnahmen:
$85.53M
Nettoeinkommen (Verlust:
$-9.78M
KGV:
-3.0202
EPS:
-2.1952
Netto-Cashflow:
$1.28M
1W Leistung:
+7.48%
1M Leistung:
+6.70%
6M Leistung:
-1.40%
1J Leistung:
+49.21%
1-Tages-Spanne:
$6.29
$6.6827
1-Wochen-Bereich:
$5.94
$6.6827
52-Wochen-Spanne:
$3.755
$9.40
Harvard Bioscience Inc Stock (HBIO) Company Profile
Firmenname
Harvard Bioscience Inc
Sektor
Telefon
(508) 893-8999
Adresse
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO vs ISRG, BDX, MDLN, ALC, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
6.61 | 27.74M | 85.53M | -9.78M | 1.28M | -2.1952 |
ISRG
Intuitive Surgical Inc
|
426.65 | 150.88B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
157.46 | 43.56B | 21.37B | 1.41B | 3.07B | 3.9437 |
MDLN
Medline Inc
|
42.83 | 36.52B | 29.14B | 1.07B | 1.05B | 1.1956 |
ALC
Alcon Inc
|
67.23 | 33.97B | 10.63B | 819.00M | 1.59B | 1.6577 |
RMD
Resmed Inc
|
219.34 | 30.41B | 5.54B | 1.52B | 1.74B | 10.37 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-04-09 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-03-10 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2021-01-07 | Hochstufung | The Benchmark Company | Speculative Buy → Buy |
| 2020-12-09 | Eingeleitet | Northland Capital | Outperform |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2019-07-08 | Herabstufung | Janney | Buy → Neutral |
| 2018-01-24 | Bestätigt | Janney | Buy |
| 2018-01-23 | Bestätigt | The Benchmark Company | Buy |
| 2016-11-17 | Eingeleitet | Singular Research | Buy |
| 2015-07-28 | Eingeleitet | The Benchmark Company | Buy |
Alle ansehen
Harvard Bioscience Inc Aktie (HBIO) Neueste Nachrichten
Harvard Bioscience | SD: Specialized disclosure report - Moomoo
HBIO Stock Price, Quote & Chart - ChartMill
Harvard Bioscience, Inc. Actuals & Estimates (NASDAQ:HBIO) - TradingView
HBIO Forecast — Price Target — Prediction for 2027 - TradingView
Price to sales forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to earnings forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Price to book forward of Harvard Bioscience, Inc. – NASDAQ:HBIO - TradingView
Harvard Bioscience Inc (HBIO) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Harvard Bioscience Inc (HBIO) Institutional Confidence - TradingKey
Harvard Bioscience Inc (HBIO) Valuation: PE, PB & Fair Value Analysis - TradingKey
Harvard Bioscience Inc (HBIO) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Harvard Bioscience holds key trading range, shares between support and resistance - AD HOC NEWS
HBIO News | HARVARD BIOSCIENCE INC (NASDAQ:HBIO) - ChartMill
Harvard Bioscience Inc (HBIO) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Harvard Bioscience Inc (HBIO) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Harvard Bioscience Inc (HBIO) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harvard Bioscience Inc (HBIO) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Harvard Bioscience Inc (HBIO) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Director at Harvard Bioscience (HBIO) granted 16,556 restricted stock units - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 restricted stock units - Stock Titan
Harvard Bioscience (NASDAQ: HBIO) awards director 16,556 RSUs - Stock Titan
Harvard Bioscience (HBIO) director awarded 16,556 RSUs in new grant - Stock Titan
Director at Harvard Bioscience (HBIO) awarded 16,556 RSUs - Stock Titan
Harvard Bioscience | 8-K: Harvard Bioscience Announces First Quarter 2026 Financial Results - Moomoo
Harvard Bioscience Shareholders Expand Equity Plans, Elect Directors - TipRanks
Harvard Bioscience (NASDAQ: HBIO) shareholders approve equity and ESPP share increases - Stock Titan
Harvard Bioscience (HBIO) price target increased by 200.00% to 6.12 - MSN
Earnings call transcript: Harvard Bioscience Q1 2026 misses EPS forecast, stock drops - Investing.com Nigeria
HBIOHarvard Bioscience Inc Website Traffic and Mobile Apps Usage - Finviz
Harvard Bioscience: HBIO stock stalls, margin pressure in focus - Bez Kabli
HBIO PE Ratio & Valuation, Is HBIO Overvalued - Intellectia AI
HBIO Q1 2026 Earnings: EPS Surprises to the Upside Despite Challenging QuarterEstimate Dispersion - thelegaladvocate.com
Harvard Bioscience Slips as Traders Assess Support Levels; HBIO Down Nearly 3%Open Trading Community - Newser
Harvard Bioscience (HBIO) Q1 2026 Earnings Beat: Revenue $N/A, EPS $-0.33Real Trader Insights - Newser
Harvard Bioscience stock (US4169061052): Q2 2025 mixed results still define the story - AD HOC NEWS
Harvard Bioscience, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:HBIO) 2026-05-15 - Seeking Alpha
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts - Investing.com UK
Earnings call transcript: Harvard Bioscience misses Q1 2026 forecasts By Investing.com - Investing.com Australia
Harvard Bioscience (HBIO) insider entity reports 293,676 shares, 6.5% stake - Stock Titan
Harvard Bioscience Transitions to Translational Science Focus in 2026 - HarianBasis.co
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q1 2026 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Inc (HBIO) Q1 2026 Earnings Call Highlights: Revenue Growth Driven by New Product Innovations - GuruFocus
Harvard Bioscience Q1 2026 slides: margins rise amid revenue miss By Investing.com - Investing.com Nigeria
Harvard Bioscience Q1 2026 Earnings Call Transcript - MarketBeat
HBIO Maintains Positive Outlook for FY26 Financial Performance - GuruFocus
Harvard Bioscience (HBIO) Reports Q1 Earnings and Reaffirms 2026 Revenue Guidance - GuruFocus
Discontinued operations of Harvard Bioscience, Inc. – FWB:HBI0 - TradingView
Harvard Bioscience Reaffirms Full-Year 2026 Financial Guidance >HBIO - Moomoo
Harvard Bioscience: Consolidation of Manufacturing Operations Progressing on Schedule >HBIO - Moomoo
Harvard Bioscience (NASDAQ: HBIO) posts Q1 2026 loss as debt costs rise - Stock Titan
Finanzdaten der Harvard Bioscience Inc-Aktie (HBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Harvard Bioscience Inc-Aktie (HBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| DENELSKY STEPHEN J | Director |
Mar 17 '26 |
Buy |
4.87 |
10,000 |
48,700 |
21,000 |
| Snider William | Director |
Mar 16 '26 |
Buy |
4.99 |
12,525 |
62,500 |
23,525 |
| Snider William | Director |
Mar 17 '26 |
Buy |
4.85 |
8,475 |
41,104 |
32,000 |
| Duke John D | Chief Executive Officer |
Mar 16 '26 |
Buy |
5.01 |
5,000 |
25,050 |
105,000 |
2.23%
2.73%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):